Panacea to start commercial production of Sputnik V from summer
Top Searches
Panacea to start commercial production of Sputnik V from summer
Rupali Mukherjee / TNN / May 24, 2021, 21:37 IST
FacebookTwitterLinkedinEMail
The first batch produced at Panacea Biotec’s facilities at Baddi will be shipped to Russia’s Gamaleya Center for quality control . (File photo)
MUMBAI: Panacea Biotec and Russia’s sovereign wealth fund, Russian Direct Investment Fund (RDIF) announced the start of production of the Sputnik V vaccine, with commercial manufacture kick-starting in summer. Under a tie-up, RDIF and Panacea have agreed to produce 100 million doses per year of the vaccine.
The first batch produced at Panacea Biotec’s facilities at Baddi will be shipped to Russia’s Gamaleya Center for quality control , a company statement said. The facilities comply with GMP (good manufacturing practices) and are prequalified by WHO, it adds.
Panacea Biotec begins Sputnik V production in India, to make 100 mn doses annually
As announced in April, the Russian Direct Investment Fund (RDIF) - which markets the vaccine internationally, and Panacea Biotec agreed to produce 100 million doses per year of Sputnik V in India
PTI | May 24, 2021 | Updated 21:18 IST
Sputnik V was registered in India under the emergency use authorisation procedure on April 12, 2021,
Domestic pharma major Panacea Biotec in collaboration with Russian sovereign wealth fund RDIF has begun the production of Sputnik V COVID-19 vaccine in India, according to a joint statement issued on Monday.
As announced in April, the Russian Direct Investment Fund (RDIF) - which markets the vaccine internationally, and Panacea Biotec agreed to produce 100 million doses per year of Sputnik V in India.
UPDATED: May 25, 2021 05:10 IST
Sputnik V was given emergency use authorisation by the Indian government on April 12 this year. (Photo: Reuters)
The Russian Direct Investment Fund (RDIF) has started the production of Sputnik V Covid-19 vaccine in India in collaboration with domestic pharma major Panacea Biotec. The joint venture is going to produce 100 million doses per year of Sputnik V in India and is expected to undergo full-scale production this summer, a joint statement issued on Monday said.
RDIF, a Russian sovereign wealth fund that markets the vaccine internationally, in April had announced a collaboration with Panacea Biotec. The first batch of the vaccine will be produced at Panacea Biotec s facilities at Baddi in Himachal Pradesh. This batch will then be shipped to Russia s Gamaleya Center for quality control , the joint statement said.